A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide

Clinical Pharmacokinetics

Volumn 32, Issue SUPPL. 1, 1997, Pages 31-36

  Tremaine, Larry M ^a,c   Wilner, Keith D ^a   Preskorn, Sheldon H ^b  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOLBUTAMIDE;

ADULT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; ENZYME INHIBITION; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PLASMA PROTEIN BINDING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT SURVEY;

EID: 0031019145     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199700321-00005     Document Type: Short Survey

References (21)

1. Veronese ME, Mackenzie PI, Doecke CJ, et al. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 1991; 175 (3): 1112-8
2. Miners JO, Smith KJ, Robson RA, et al. Tolhutamide hydroxylation by human liver microsomes. Kinetic characterization and relationship to other cytochrome P-450-dependent xenobiotic oxidations. Biochem Pharmacol 1988; 37: 1137-44
3. Davis JM, Glassman AH. Antidepressant drugs. In: Kaplan HI, Sadock BJ, editors. Comprehensive textbook of psychiatry. 5th ed. Baltimore: Williams & Wilkins, 1989: 1627-55
4. Feighner JP, Boyer WF. Selective serotonin re-uptake inhibitors. New York: John Wiley, 1991: 81-7
5. Goodnick PJ, Henry JH, Buki VM. Treatment of depression in patients with diabetes mellitus. J Clin Psychiatry 1995; 56: 128-36
6. Nation RL, Peng GW, Chiou WL, et al. Simple, rapid and micro high-pressure liquid chromatographic method for the simultaneous determination of tolbutamide and carboxytolbutamide in plasma. J Chromatogr 1978; 146: 121-31
7. Tremaine LM, Welch WM, Ronfeld RA. Metabolism and disposition of the 5-hydroxytryptamine uptake blocker sertraline in the rat and dog. Drug Metab Dispos 1989; 17: 542-50
8. Tremaine LM, Joerg EA. Automated gas chromatographic-electron-capture assay for the selective serotonin uptake blocker sertraline. J Chromatogr 1989; 496: 423-9
9. Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 1997; 32 Suppl. 1: 22-30
10. Preskorn SH, Lane RM. Sertraline 50mg daily: the optimal dose in the treatment of depression. Int Clin Psychopharmacol 1995; 10: 129-41
11. Apseloff G, Wilner KD, Gerber N, et al. Effect of sertraline on protein binding of warfarin. Clin Pharmacokinet 1997; 32 Suppl. 1: 37-42
12. Back DJ, Orme ML. Genetic factors influencing the metabolism of tolbutamide. Pharmacol Ther 1989; 44: 147-55
13. Newton DJ, Wang RW, Lu AYH. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995; 23: 154-8
14. Pond SM, Birkett DJ, Wade DN. Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone and sulphaphenazole. Clin Pharmacol Ther 1977; 22: 573-9
15. Miners JO, Foenander T, Wanwimolruk S, et al. The effect of sulphinpyrazone on oxidative drug metabolism in man: inhibition of tolbutamide elimination. Eur J Clin Pharmacol 1982; 22: 321-6
16. Back DJ, Tija J, Monig H, et al. Selective inhibition of drug oxidation after simultaneous administration of two probe drugs, antipyrine and tolbutamide. Eur J Clin Pharmacol 1988; 34: 157-63
17. Veronese ME, Miners JO, Randles D, et al. Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers. Clin Pharmacol Ther 1990; 47: 403-11
18. Rapeport WG, Muirhead DC, Williams SA, et al. Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. J Clin Psychiatry 1996; 57 Suppl. 1: 24-8
19. Warrington SJ. Clinical implications of the pharmacology of sertraline. Int Clin Psychopharmacol 1991; 6 Suppl. 2: 11-21
20. Lemberger L, Bergstrom RF, Wolen RL, et al. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry 1985; 46 (3 Pt 2): 14-9
21. Juan D, Molitch ME, Johnson MK, et al. Unaltered drug metabolizing enzyme systems in type II diabetes mellitus before and during glyburide therapy. J Clin Pharmacol 1990; 30: 943-7